相关实验视频
Updated: Jun 9, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.8K
非免疫性复合性稳基酶与大规模肺栓塞患者的阿尔特酶:随机开放标签,多中心,并行组,非劣势试验,FORPE
Alexander I Kirienko1, Stanislav G Leontyev1, Sergey N Tereschenko2
1Department of Faculty Surgery, N.I. Pirogov Russian National Research Medical University, Moscow, Russia.
Journal of thrombosis and haemostasis : JTH
|October 25, 2024
概括
非免疫性稳酶在治疗大规模肺栓塞时,已证明与阿尔特普拉斯无劣. 这种新型血栓抑制剂的疗效与潜在改善的安全性概况相提并论,减少了重大出血事件.
科学领域:
- 心脏病学 心脏病学
- 血栓形成研究研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 非免疫性稳定酶是一种新型重组血栓解压剂,旨在降低免疫性和增强纤维素选择性.
- 带有血液动力学不稳定的大规模肺栓塞 (PE) 是一个关键的治疗挑战,需要有效和安全的血栓溶解干预措施.
研究的目的:
- 在患有大规模肺栓塞的患者中,评估非免疫性稳定酶与阿尔特普拉斯相比的非劣势性.
- 为了评估一次性静脉注射非免疫性稳定酶的单剂量注射的安全性和有效性.
主要方法:
- 一个随机的,开放的,多中心的,非劣等性试验 (FORPE) 涉及310名确诊的大型PE和右心室功能障碍的患者.
- 患者接受了非免疫性稳定酶 (15 mg 输入) 或高高 (100 mg 输入).
- 主要疗效终点是随机化后7天内全因死亡率.
主要成果:
- 发现非免疫性稳定酶与阿尔特相比并非劣,治疗组的死亡率为2%,而阿尔特组的死亡率为3% (OR 0.75;95% CI,0.11-4.49).
- 主要疗效终点的95%置信区间下限没有超过非劣势差额.
- 一个值得注意的安全性发现是,非免疫原性稳基因酶组中没有严重出血,而阿尔特酶组中这一比例为3% (P=.09).
结论:
- 非免疫性稳酶是一种可行的,不劣等的替代品,用于治疗大规模肺栓塞.
- 这项研究表明,非免疫性稳定酶的安全性可能是有利的,特别是在严重出血方面.
- 建议进行进一步的观察性研究,以证实非免疫性稳定酶在临床实践中的长期安全性和有效性.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis III: Interprofessional Care
2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
Pulmonary Embolism III: Nursing Management
1
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
1
Acute Coronary SyndromeI: Introduction
3
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154

